• Profile

Safety and efficacy of interleukin-6-receptor inhibitors in the treatment of neuromyelitis optica spectrum disorders: A meta-analysis

BMC Neurology Dec 01, 2021

Kharel S, Shrestha S, Ojha R, et al. - Neuromyelitis Optica spectrum disorder (NMOSD) can be successfully treated with interleukin-6-receptor inhibitors therapy, with promising results with good efficacy and acceptable adverse events profile.

  • Relevant studies (nine studies with 202 patients) were selected from PubMed, Embase, and The Cochrane Library, to determine the efficacy as well as safety of various interleukin-6-receptor inhibitors in the management of NMO/NMOSD.

  • Tocilizumab provided freedom from relapse in a good proportion (76.95% CI: 0.61–0.91; p < 0.001) of patients and significantly decreased mean Annualized Relapse Ratio (ARR) (mean difference: -2.6, 95% CI: − 2.71 to − 1.68; p < 0.001), with an acceptable toxicity profile.

  • In SAkura studies for Satralizumab, similar relapse free patients (70% to 80%) and reduction of ARR and Extended Disability Status Scale from baseline was evident.

  • Reduction of pain and fatigue with tocilizumab was revealed in some studies while trials of Satralizumab demonstrated non-significant findings.

Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
  • Exclusive Write-ups & Webinars by KOLs

  • Nonloggedininfinity icon
    Daily Quiz by specialty
  • Nonloggedinlock icon
    Paid Market Research Surveys
  • Case discussions, News & Journals' summaries
Sign-up / Log In
M3 app logo
Choose easy access to M3 India from your mobile!

M3 instruc arrow
Add M3 India to your Home screen
Tap  Chrome menu  and select "Add to Home screen" to pin the M3 India App to your Home screen